Glaxosmithkline Share News (GSK)

TOP NEWS: GlaxoSmithKline Submits Shingles Drug For US Approval

LONDON BRIEFING: NCC, Keller And Senior Drop After Trading Updates

UK Earnings, Trading Statements Calendar - Next 7 Days

WHO seeks new mechanism for crisis vaccine supplies at low cost

By Kate Kelland, Health and Science Correspondent LONDON, Oct 19 (Reuters) - The World Health Organization, drugmakers and humanitarian groups are hammering out details of a new vaccine supply system aimed at getting vital shots to vulnerable people in crises such as wars or natural disaste

Sector movers: Tesco leads cyclicals higher, pharma drags

(ShareCast News) - Cyclicals took over from defensives, with Tesco spearheading gains among food and drug retailers while pharma stocks acted as the main drag. Tesco shares accounted for the lion's share of the gains in that sector after Unilever said issues surrounding the supply of its leading bra

BROKER RATINGS SUMMARY: Investec Starts Wolseley With Hold Rating

Q&A-Pound plunges, stocks up, economy flat: What do Brexit swings mean for you?

By Guy Faulconbridge, Jamie McGeever and David Milliken LONDON, Oct 7 (Reuters) - Sterling has tumbled to a 31-year low, but British stocks are near a record high and, contrary to many expert forecasts, the shock of Brexit has not yet pushed the British economy off a cliff. So what gi

Q&A-Pound down, stocks up, economy flat: What do Brexit swings mean for you?

By Guy Faulconbridge, Jamie McGeever and David Milliken LONDON, Oct 5 (Reuters) - Sterling has tumbled to a 31-year low, but British stocks are near a record high and, contrary to many expert forecasts, the shock of Brexit has not pushed the British economy off a cliff. So what gives?

UPDATE 1-GlaxoSmithKline to pay $20 mln to settle U.S. foreign bribery case

(Adds company statement and that U.S. Justice Department has closed its case without charges, background, SEC case details) By Sarah N. Lynch WASHINGTON, Sept 30 (Reuters) - GlaxoSmithKline Plc will pay $20 million to settle civil charges that it masked bribes to foreign officials in

GlaxoSmithKline to pay $20 mln to settle foreign bribery related charges

By Sarah N. Lynch WASHINGTON, Sept 30 (Reuters) - GlaxoSmithKline will pay $20 million to settle civil charges that it masked improper bribes to foreign officials in China on its books by disguising them as legitimate travel, entertainment and marketing expenses, U.S. regulators said Friday

After CEO move, GSK picks ex-Novartis exec to head consumer unit

LONDON, Sept 29 (Reuters) - GlaxoSmithKline has promoted a former Novartis executive to lead its consumer healthcare business, following the appointment last week of the unit's previous head, Emma Walmsley, as CEO designate of the drugmaker. The British group said on Thursday that Brian McN

GlaxoSmithKline raises £477m from offloading final Aspen shares

(ShareCast News) - GlaxoSmithKline has sold its remaining shares in South Africa's Aspen Pharmacare to raise 8.47bn rand (£477m). The FTSE 100 drugs and consumer healthcare group agreed to sell its final holding of 28.2m ordinary shares at a price of 300 South African rand per share and so no longer

GSK in deal to produce Israeli nutritional growth formula to children

JERUSALEM, Sept 28 (Reuters) - * GlaxosmithKline Consumer Healthcare has entered into a licence agreement with Israel's Nutritional Growth Solutions (NG Solutions) for Horlicks Growth+, a formula aimed at boosting height and weight in short and thin children aged 3 to 9, NG said on Wednesda

Glaxo files US regulatory submission for sirukumab

(ShareCast News) - GlaxoSmithKline has filed a regulatory submission to the US Food and Drug Administration for the use of sirukumab for the treatment of rheumatoid arthritis. More specifically, it is for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) wh

NEWSMAKER-Breaking the mould: GSK picks Big Pharma's first female CEO

* New CEO is consumer brands specialist * Appointment seen as backing diversification strategy * Walmsley stresses importance of developing new drugs By Ben Hirschler LONDON, Sept 20 (Reuters) - Emma Walmsley, GlaxoSmithKline's incoming CEO, breaks the mould as the first